课题基金 / 基金详情

PHASE II STUDY OF RECOMBINANT BETA AND GAMMA INTERFERON IN LUNG CANCER

PHASE II STUDY OF RECOMBINANT BETA AND GAMMA INTERFERON IN LUNG CANCER
重组 β 和 γ 干扰素治疗肺癌的 II 期研究
批准号：
3904524
负责人：
RONALD BLUM
金额：
$0.0万
依托单位：
NEW YORK UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3904524
关键词：
combination cancer therapy human subject human therapy evaluation immunological substance interferons lung neoplasms metastasis monocyte neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy tumor necrosis factor alpha

项目摘要

项目成果

RONALD BLUM的其他基金

相似基金

相关文献

中文摘要
翻译
本研究旨在确定联合重组的毒性 干扰素γ和β-丝氨酸在非小细胞肺癌患者中应用 肺癌;该疗法的反应率，通过 无病生存期和总生存期;免疫调节活性 通过诱导TNF来测量这种联合治疗的效果; II类HLA抗原在单核细胞上的表达及其与 生存;这种联合治疗的免疫调节活性， 通过TNF的诱导来测量; 单核细胞以及其与临床反应的相关性。
英文摘要
This study will to determine the toxicity of combined recombinant interferon gamma and beta serine in patients with metastic non-small cell carcinoma of the lung; the response rate of this therapy as measured by disease-free survival and overall survival; the immune-modifying activity of this combined therapy as measured by induction of TNF; the expression of Class II HLA antigen on monocytes and the correlation of this to survival; the immune-modifying activity of this combined therapy as measured by induction of TNF; the expression of Class II HLA antigen on monocytes and the correlation of this to clinical response.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ECOG C9344 DOXORUBICIN DOSE ESCALATION +/- TAXOL FOR NODE POSITIVE BREAST CANCER
SWOG 94-20 CORRELATION OF THYMIDYLATE SYNTHASE IN 5 FU TREATED COLORECTAL CANCER
ECOG S9313--ADJUVANT CHEMOTHERAPY IN HIGH RISK BREAST CANCER PATIENTS
ECOG 91140--CDP, DTIC, CARMUSTINE & TAMOXIFEN VS DTIC IN ADVANCED MELANOMA
海外基金